BACKGROUND: Myxoid/round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for >33% of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY-ESO-1 is a cancer-testis antigen (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors. METHODS: The authors investigated the feasibility of targeting NY-ESO-1 in patients with MRCL by evaluating the prevalence of NY-ESO-1 expression in tumors using immunohistochemistry and quantitative reverse transcriptase-polymerase chain reaction analysis. NY-ESO-1-specific tumor recognition by NY-ESO-1-specific T-cells also was analyzed using a chromium release assay. RESULTS: A search of the University of Washington Sarcoma Tissue Bank identified paraffin-embedded tumor samples from 25 patients with MRCL. NY-ESO-1 expression was observed in every MRCL tumor assessed (100%); in 18 tumors (72%), staining was homogenous. In all but 2 tumors, staining was sufficiently robust (2+) that such patients would be eligible for clinical trials of NY-ESO-1-directed therapy. By using NY-ESO-1 specific, CD8-positive T-cells, the in vitro sensitivity of myxoid liposarcoma cell lines to antigen-specific lysis was demonstrated. CONCLUSIONS: The current results establish NY-ESO-1 as an important target antigen for the treatment of patients with MRCL.
BACKGROUND: Myxoid/round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for >33% of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY-ESO-1 is a cancer-testis antigen (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors. METHODS: The authors investigated the feasibility of targeting NY-ESO-1 in patients with MRCL by evaluating the prevalence of NY-ESO-1 expression in tumors using immunohistochemistry and quantitative reverse transcriptase-polymerase chain reaction analysis. NY-ESO-1-specific tumor recognition by NY-ESO-1-specific T-cells also was analyzed using a chromium release assay. RESULTS: A search of the University of Washington Sarcoma Tissue Bank identified paraffin-embedded tumor samples from 25 patients with MRCL. NY-ESO-1 expression was observed in every MRCL tumor assessed (100%); in 18 tumors (72%), staining was homogenous. In all but 2 tumors, staining was sufficiently robust (2+) that such patients would be eligible for clinical trials of NY-ESO-1-directed therapy. By using NY-ESO-1 specific, CD8-positive T-cells, the in vitro sensitivity of myxoid liposarcoma cell lines to antigen-specific lysis was demonstrated. CONCLUSIONS: The current results establish NY-ESO-1 as an important target antigen for the treatment of patients with MRCL.
Authors: Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee Journal: N Engl J Med Date: 2008-06-19 Impact factor: 91.245
Authors: Cyril Cuffel; Jean-Paul Rivals; Yannick Zaugg; Suzanne Salvi; Walter Seelentag; Daniel E Speiser; Danielle Liénard; Philippe Monnier; Pedro Romero; Luc Bron; Donata Rimoldi Journal: Int J Cancer Date: 2010-10-08 Impact factor: 7.396
Authors: P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon Journal: Science Date: 1991-12-13 Impact factor: 47.728
Authors: Theo Nicholaou; Lisa M Ebert; Ian D Davis; Grant A McArthur; Heather Jackson; Nektaria Dimopoulos; Bee Tan; Eugene Maraskovsky; Lena Miloradovic; Wendie Hopkins; Linda Pan; Ralph Venhaus; Eric W Hoffman; Weisan Chen; Jonathan Cebon Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531
Authors: P Aman; D Ron; N Mandahl; T Fioretos; S Heim; K Arheden; H Willén; A Rydholm; F Mitelman Journal: Genes Chromosomes Cancer Date: 1992-11 Impact factor: 5.006
Authors: I Panagopoulos; N Mandahl; D Ron; M Höglund; M Nilbert; F Mertens; F Mitelman; P Aman Journal: Cancer Res Date: 1994-12-15 Impact factor: 12.701
Authors: Maha Ayyoub; Robert N Taub; Mary-Louise Keohan; Mary Hesdorffer; Genevieve Metthez; Lorenzo Memeo; Mahesh Mansukhani; Hanina Hibshoosh; Charles S Hesdorffer; Danila Valmori Journal: Cancer Immun Date: 2004-08-09
Authors: Marieke A de Graaff; Jamie S E Yu; Hannah C Beird; Davis R Ingram; Theresa Nguyen; Jeffrey Juehui Liu; Svetlana Bolshakov; Károly Szuhai; Pierre Åman; Keila E Torres; Dina Lev; Torsten O Nielsen; Judith V M G Bovée; Alexander J Lazar; Neeta Somaiah Journal: Lab Invest Date: 2016-06-06 Impact factor: 5.662
Authors: Shihong Zhang; Karan Kohli; R Graeme Black; Lu Yao; Sydney M Spadinger; Qianchuan He; Venu G Pillarisetty; Lee D Cranmer; Brian A Van Tine; Cassian Yee; Robert H Pierce; Stanley R Riddell; Robin L Jones; Seth M Pollack Journal: Cancer Immunol Res Date: 2019-06-06 Impact factor: 11.151
Authors: Jessica A Hemminger; Amanda Ewart Toland; Thomas J Scharschmidt; Joel L Mayerson; Denis C Guttridge; O Hans Iwenofu Journal: Mod Pathol Date: 2014-01-24 Impact factor: 7.842
Authors: Makoto Endo; Marieke A de Graaff; Davis R Ingram; Simin Lim; Dina C Lev; Inge H Briaire-de Bruijn; Neeta Somaiah; Judith V M G Bovée; Alexander J Lazar; Torsten O Nielsen Journal: Mod Pathol Date: 2014-11-21 Impact factor: 7.842
Authors: Karan Kohli; Lu Yao; Theodore Scott Nowicki; Shihong Zhang; Ralph Graeme Black; Brett A Schroeder; Erik A Farrar; Jianhong Cao; Heather Sloan; Dawn Stief; Lee D Cranmer; Michael J Wagner; Douglas S Hawkins; Venu G Pillarisetty; Antoni Ribas; Jean Campbell; Robert H Pierce; Edward Y Kim; Robin L Jones; Stanley R Riddell; Cassian Yee; Seth M Pollack Journal: J Immunother Cancer Date: 2021-05 Impact factor: 13.751